177Lu-PSMA-617与177Lu-PSMA I&T在转移性去势抵抗性前列腺癌中的总生存比较:倾向性评分匹配的真实世界分析
单中心回顾性匹配分析纳入140例化疗后转移性去势抵抗性前列腺癌患者,比较177Lu-PSMA-617(7.4 GBq每6周,n=70)与177Lu-PSMA I&T(6.0 GBq每8周,n=70)的疗效与安全性。匹配后两组中位总生存无显著差异(15个月 vs 14个月,HR 1.18,95%CI 0.79-1.78,P=0.42);617组PSA下降幅度和生化反应率更高,但CTCAE分级毒性相当。
要点
- 匹配后617与I&T中位OS无显著差异(15 vs 14个月,P=0.42)。
- 617组PSA下降幅度(-58% vs -14%)及生化反应率(70% vs 54%)更高。
- 两药CTCAE分级毒性相当,早期PSA反应与更长OS相关。
核心结论
- 尽管治疗方案不同,177Lu-PSMA I&T与177Lu-PSMA-617治疗后的生存结局相当。
- 617组生化反应更强及亚临床血液学变化更明显,可能反映更高的累积辐射暴露,但缺乏患者特异性剂量学数据证实。
研究设计与样本
- 单中心回顾性配对分析,纳入140例化疗后转移性去势抵抗性前列腺癌患者。
- 患者接受177Lu-PSMA-617(7.4 GBq每6周,n=70)或177Lu-PSMA I&T(6.0 GBq每8周,n=70)。
- 基于年龄、基线PSA和PSA阳性肿瘤体积进行倾向性评分匹配,并按Gleason评分分层。
主要发现
- 匹配后中位OS:I&T组14个月(范围9-16),617组15个月(范围10-21),HR 1.18,95%CI 0.79-1.78,P=0.42。
- 早期PSA反应与两组更长OS均强相关(P<0.01)。
- 617组中位PSA下降幅度更大(-58% vs -14%,P=0.02),生化反应率更高(70% vs 54%)。
- 617组定量血液学变化更明显,但CTCAE分级毒性两组相当。
- 多变量分析显示,较高基线LDH与两组更短OS显著相关(每10 U/L HR 1.03-1.04,P<0.01)。
关键数值与推荐
- 177Lu-PSMA-617给药方案:7.4 GBq每6周。
- 177Lu-PSMA I&T给药方案:6.0 GBq每8周。
- 匹配后中位OS:I&T 14个月(范围9-16),617 15个月(范围10-21)。
- 生化反应率:617组70%,I&T组54%;中位PSA下降:617组-58%,I&T组-14%(P=0.02)。
- 基线LDH每升高10 U/L,OS的HR为1.03-1.04(P<0.01)。
临床怎么用
- 在缺乏头对头随机试验时,真实世界数据提示两种177Lu-PSMA药物生存结局相当,药物选择可综合考虑可及性与方案便利性。
- 治疗早期PSA反应可作为预后参考指标,反应不佳者需关注后续治疗策略。
- 基线LDH升高提示预后较差,可作为风险分层与随访强度的参考。
- 617组血液学变化更明显但CTCAE毒性相当,治疗中仍需常规监测血液学指标。
局限性
- 单中心回顾性设计,样本量有限(匹配后每组70例),存在选择偏倚可能。
- 缺乏患者特异性剂量学数据,无法证实累积辐射暴露差异的假设。
- 两种药物给药方案不同(7.4 GBq每6周 vs 6.0 GBq每8周),可能影响比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In this study, we compared clinical outcomes and safety profiles of radiopharmaceutical therapy with [177Lu]Lu-PSMA-617 and [177Lu]Lu-PSMA I&T in patients with metastatic castration-resistant prostate cancer under real-world conditions. Methods: This single-center retrospective matched-pair analysis included 140 chemotherapy-pretreated patients with metastatic castration-resistant prostate cancer treated with commercially available [177Lu]Lu-PSMA-617 (7.4 GBq every 6 wk) (n = 70) or in-house produced [177Lu]Lu-PSMA I&T (6.0 GBq every 8 wk) (n = 70). Propensity score matching was performed on the basis of age, baseline prostate-specific antigen (PSA), and PSA-positive tumor volume and stratified by Gleason score. Overall survival (OS), biochemical response, prognostic factors, and treatment-related toxicity were analyzed. Results: Median OS was comparable between matched cohorts ([177Lu]Lu-PSMA I&T: 14 mo; range, 9-16 mo; [177Lu]Lu-PSMA-617: 15 mo; range, 10-21 mo); hazard ratio, 1.18; 95% CI, 0.79-1.78; P = 0.42). Early PSA response was strongly associated with prolonged OS in both cohorts (P < 0.01). Patients treated with [177Lu]Lu-PSMA-617 demonstrated a greater median PSA decline (-58% vs. -14%, P = 0.02) and higher biochemical response rates (70% vs. 54%). Although quantitative hematologic changes were more pronounced with [177Lu]Lu-PSMA-617, Common Terminology Criteria for Adverse Events-graded toxicity remained comparable between cohorts. Multivariable analysis revealed that higher baseline levels of lactate dehydrogenase were significantly associated with shorter OS in both cohorts (hazard ratio, 1.03-1.04 per 10 U/L, P < 0.01). Conclusion: Treatment with [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 resulted in comparable survival outcomes despite different treatment protocols. Greater biochemical responses and subclinical hematologic changes with [177Lu]Lu-PSMA-617 may reflect higher cumulative radiation exposure, although patient-specific dosimetry data were not available to confirm this hypothesis.
引用
- Hasenauer N, Probst C, Schloetelburg W, et al. Overall Survival with [177Lu]Lu-PSMA-617 Versus [177Lu]Lu-PSMA I&T: A Propensity Score-Matched Real-World Analysis. J Nucl Med. 2026. PMID: 42392698. doi:10.2967/jnumed.126.272415
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。